To: Board of Supervisors
From: Anna Roth, Health Services Director
Report Title: Purchase Order with Organon LLC
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, a purchase order with Organon LLC in an amount not to exceed $600,000, and Product Agreement for the purchase of JADA System devices for Contra Costa Regional Medical Center (CCRMC) effective the date the agreement is signed and for two years thereafter.
FISCAL IMPACT:
Approval of this action will result in expenditures of up to $600,000 over a twenty-four month period and will be funded by Hospital Enterprise Fund I revenues.
BACKGROUND:
The JADA System is a relatively new intrauterine device that uses low-level vacuum to stimulate natural uterine contraction forces to decrease abnormal postpartum uterine bleeding or postpartum hemorrhage after childbirth. When connected to a low-level vacuum source, JADA establishes a vacuum within the uterus, causing the uterus to contract and leading to control of bleeding.
This system was designed to have broad application in high and low-income countries, and is fast and easy to use, which is critical when stabilizing a hemorrhaging patient during birth. The JADA system can provide visible and observable control of bleeding within minutes. It has a short treatment time while providing immediate, effective control of abnormal postpartum uterine bleeding and postpartum hemorrhage.
On November 8, 2023 the Purchasing Agent approved the use of Organon LLC. The department provided a letter from the company stating it was the exclusive provider of this product.
The Organon LLC Product Agreement requires the County to pay for costs and reasonable attorney’s fees if Organon undertakes collection. Additionally, the agreement includes a limitation of liability provision, which requires the County to defend, indemnify, and hold Organon LLC harmless. Approval of this request will allow Organon LLC to provide JADA System devices to decrease abnormal postpartum uterine bleeding.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, women with heavy postpartum hemorrhaging will be more likely to experience negative to severe outcomes, such as drop in blood pressure resulting in shock and possibly death.